JNJ-64300535

BIOLOGICAL3 trials

Sponsors

Janssen Sciences Ireland UC, Janssen Research & Development, LLC

Conditions

HealthyHepatitis B, Chronic

Phase 1

A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

CompletedNCT03463369

Janssen Sciences Ireland UCHepatitis B, Chronic

Start: 2018-04-18End: 2021-03-23Updated: 2021-04-14

A Study of JNJ-64300535 in Healthy Participants

CompletedNCT04736147

Janssen Research & Development, LLCHealthy

Start: 2021-02-03End: 2021-12-07Updated: 2021-12-22

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

CompletedNCT05123599

Janssen Research & Development, LLCHepatitis B, Chronic

Start: 2021-12-06End: 2024-06-26Updated: 2025-05-26